VivoSeq
Hematology

Deep Vein Thrombosis

32

Pipeline Programs↗

4

Active Trials↗

15

Companies Involved↗

Deep Vein Thrombosis is a moderately active landscape with 32 programs across 15 companies. The most active players are Pfizer, Roche, AstraZeneca. 14 therapies are approved with 10 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

53/100

Pipeline Velocity

0/100

Mech. Concentration

27/100

Completion Rate

89/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

1 program

Phase 2Roche logo

Roche

1 program

Phase 2AstraZeneca logo

AstraZeneca

1 program

Phase 2R

rEVO Biologics

1 program

Phase 3Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 3Novartis logo

Novartis

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

97%

Small molecule

35 of 36 classified programs — the dominant modality here.

3%ALL OTHERSProtein / enzyme13%

Small molecule leads; the ring shows all 36 classified programs, each share of the total. Modality classified for 100% of 38 pipeline programs.

Analysis

Trial Status

49

clinical trials

Completed31 · 63%
Unknown status10 · 20%
Terminated4 · 8%
Recruiting2 · 4%
Active, not recruiting1 · 2%
Enrolling by invitation1 · 2%

Clinical Trials

Trial Activity

49 trials

Secondary Prevention of VTE in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis
Recruiting·OOttawa Hospital Research Institute·Phase 4·NCT06603870·330 enrolled
Rivaroxaban for the Prevention of Deep Vein Thrombosis in Patients With Left Iliac Vein Compression - The PLICTS Study
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT04067505·224 enrolled
Effect of Tinzaparin on Inflammatory Biomarkers During the Acute Phase of Deep Vein Thrombosis
Active, not recruiting·—·N/A·NCT04741464·9 enrolled
ClotTriever® Thrombectomy System Use-Result Survey in Japan
Enrolling by invitation·IInari Medical·N/A·NCT06871683·100 enrolled
Generation of Thrombin and Prediction of Deep Vein Thrombosis Post Prosthetic Orthopedic Surgery of the Lower Limbs
Completed·—·Phase 3·NCT03634124·146 enrolled
Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 3·NCT00633893·2,711 enrolled
A Study to Learn More About How Well BAY3018250 Works and How Safe it is for People With Proximal Deep Vein Thrombosis
Completed·Bayer logoBayer·Phase 2·NCT06149520·258 enrolled
Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT)
Completed·Bayer logoBayer·Phase 2·NCT00839163·613 enrolled
Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). A Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement.
Completed·Bayer logoBayer·Phase 3·NCT00361894·2,531 enrolled
A Safety and Efficacy Study of BCD-080 Compared to Clexan for Deep Vein Thrombosis Prophylaxis at Orthopedic Surgeries
Completed·BBiocad·Phase 3·NCT02368314·124 enrolled
Rivaroxaban With Diosmin in Long-term Treatment of Deep Vein Thrombosis
Completed·PPirogov Russian National Research Medical University·Phase 4·NCT03413618·90 enrolled
Treatment of Chronic Deep Vein Thrombosis (DVT) and Post-Thrombotic Syndrome (PTS) With the EkoSonic® Endovascular System
Completed·BBoston Scientific Corporation·Phase 4·NCT02159521·81 enrolled
Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer
Completed·Bayer logoBayer·Phase 2·NCT00786422·25 enrolled
Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients With Cancer Study
Completed·—·Phase 4·NCT03895502·605 enrolled
Safety and Efficacy Trial Evaluating the Use of SR34006 in the Treatment of Deep Vein Thrombosis (DVT)
Completed·Sanofi logoSanofi·Phase 3·NCT00067093·1,452 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)